2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

621. Lymphomas: Translational: Molecular and Genetic: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Non-Biological Therapies, Pharmacology, Biological Processes, Apoptosis, Pathogenesis, CHIP, Genomics, Hematopoiesis, Immune Mechanism, Molecular Biology, Diseases, Lymphoid Malignancies, Lymphomas, Plasma Cell Disorders, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, Translational Research, Clinical Research, Clinical Trials, Real-World Evidence, Study Population, Human, Adult, Elderly, Animal Model
PAPER

1738 A multi-cohort analysis of clinical, molecular, and genomic features of IPI 1–2 with bulky disease and/or elevated LDH in newly diagnosed DLBCL reveals poor clinical outcome and upregulation of aggressive growth pathways

Matthew E. Stokes, Kerstin Wenzl2, Charalampos Kyriakopoulos3, Alberto Risueño4, Andrew Davies, PhD, BSc5, Peter Johnson, MD6, Joshua Caddy7, Louise Ruth Stanton, MSc. BSc Medical Statistics8, Anita Gandhi, PhD9, C. Chris Huang10, Mark Kaplan, PhD11
1 Bristol Myers Squibb, Madison, New Jersey, United States
2 Bristol Myers Squibb, Madison, New Jersey, United States
3 Bristol Myers Squibb, Cambridge, Massachusetts, United States
4 Bristol Myers Squibb, Princeton, New Jersey, United States
5 Southampton NIHR/Cancer Research UK Experimental Cancer Medicines Centre, Southampton, United Kingdom
6 Cancer Research UK Centre, Southampton, United Kingdom
7 Cancer Research UK Centre, Southampton, United Kingdom
8 Southampton Clinical Trials Unit, Southampton, United Kingdom
9 Bristol Myers Squibb, Madison, New Jersey, United States
10 Bristol Myers Squibb, Madison, New Jersey, United States
11 Bristol Myers Squibb, Madison, New Jersey, United States

Introduction

The International Prognostic Index (IPI) is a well-validated method for risk stratification in newly diagnosed diffuse large B-cell lymphoma. However, its clinical utility has been limited. Maurer et al (2023) proposed a reclassification of IPI 1–2 into low- and high-risk IPI 1–2 subgroups according to the presence or absence of bulky disease (≥7–10 cm) and/or elevated lactate dehydrogenase (LDH) (>1.3× upper limit of normal) and demonstrated that the high-risk group exhibited survival outcome similar to that of the IPI 3 group. Using 4 independent clinical cohorts, we explored the survival profile of these IPI subgroups, as well as the biological differences between them, using transcriptomic and genomic data.

Methods

The redefined IPI 1–2 subgroups, referred to as HR IPI 1–2 and LR IPI 1–2, along with IPI 3 and IPI 4–5, were evaluated across 1 real-world dataset, MER (n=277), and 3 prospective clinical trial datasets: ROBUST (n=438), REMoDL-B (n=820), and GOYA (n=269). Analyses were performed across multiple dimensions, including: (1) survival outcomes among R-CHOP–treated patients; (2) clinical feature profiling, including IPI component prevalence and demographic characteristics; (3) gene expression and pathway analysis; (4) mutational profiling and copy number variation; and (5) molecular subtype classification, including cell of origin (COO), DZsig, EFS24sig, TME26, SubLymE, and LymphGen.

Results

Clinical Outcomes. Inferior progression-free survival (PFS) of HR IPI 1–2 was consistently validated across all 4 cohorts, showing worse outcome than LR IPI 1–2 in all cohorts (with a hazard ratio [HR] between 1.4 and 2.1) and with similar outcome to IPI 3 in some cohorts, confirming a higher risk than LR IPI 1–2.

Clinical Feature Profile. HR IPI 1–2 patients were significantly younger than both LR IPI 1–2 and IPI 3–5 counterparts by approximately 5 to 10 years across datasets and exhibited elevated LDH at a rate similar to that of IPI 3–5 patients, in sharp contrast to LR IPI 1–2 patients. Cox proportional hazards modeling identified LDH as the single most prognostically impactful high-risk IPI factor (HR, 2.00–2.70 across cohorts), underscoring the clinical rationale for selecting this population.

Molecular Subtype Analysis. No statistically significant enrichment of established molecular subtypes was observed in HR IPI 1–2 compared with LR IPI 1–2 or IPI 3–5, including COO (GCB/ABC), DZsig, TME26, SubLymE, EFS24sig, or LymphGen.

Gene Expression Pathways. Gene expression profiling revealed consistent upregulation of cell-cycle– and growth-related hallmark pathways in HR IPI 1–2 relative to LR IPI 1–2, specifically G2M checkpoint, E2F targets, and mTORC1 signaling. Upregulation of these pathways was also observed in higher-IPI groups, increasing in a stepwise fashion from lowest to highest IPI, with no significant differences between HR IPI 1–2 and IPI 3 or IPI 4–5.

Genomic Analysis. No mutations or copy number features reached significance after false discovery rate correction across cohorts. ARID1A showed an elevated mutation rate in HR IPI 1–2 in some individual datasets; ARID1A is a known component of the EFS24 poor-prognosis gene signature. No other consistent mutational associations were identified.

Conclusions

Across 4 independent cohorts with newly diagnosed DLBCL, HR IPI 1–2 consistently demonstrated inferior survival outcomes compared with LR IPI 1–2, without enrichment for any established molecular DLBCL subtypes. The molecular signature of HR IPI 1–2 was characterized by upregulation of cell-cycle and proliferative pathways (G2M, E2F, mTORC1), consistent with the biology of tumors defined clinically by bulky disease and elevated LDH. The younger median age of patients with HR IPI 1–2 indicates that HR IPI 1–2 represents a unique subset of nontraditional risk, reversing the typical association of higher age and higher risk. These findings identify HR IPI 1–2 as a clinically meaningful, molecularly heterogeneous high-risk subgroup not readily captured by existing molecular classifiers, supporting its utility as a clinical enrichment criterion in clinical studies. These patients may require more intensive therapy than standard-of-care immunochemotherapy. The GOLSEEK-1 study (NCT06356129) includes patients with HR IPI 1–2 and aims to evaluate the benefit of adding golcadomide to R-CHOP in patients with previously untreated high-risk LBCL.

Matthew E. Stokes: BMS - Current equity holder in publicly-traded company; BMS - Divested equity in a private or publicly-traded company in the past 24 months; BMS - Current Employment